Proportion of patients with pre-HCT CMV reactivation and pre-HCT CMV DNA PCR levels by number of risk factors. Proportion of patients with detectable CMV DNAemia by PCR from 1 to 90 days before HCT (left) and corresponding levels of pre-HCT CMV DNAemia in these patients (right) stratified by the number of pre-HCT risk factors present, including HCT-CI score ≥3, absolute lymphocyte count ≤0.3× 10³/μL, and underlying lymphoid malignancy.